Purchase Order HHSN261201700540P

<p>The National Cancer Institute awarded a purchase order to Microfluidic Chipshop GMBH for laboratory supplies on July 26, 2018, with a ceiling value of $19,414.50. Work is performed in Germany. The order is firm fixed price and was completed by September 30, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Deutsches Krebsforschungszentrum on September 18, 2017, with a ceiling value of $18,876.00 under firm fixed-price terms. Performance is located in Germany, with an ultimate completion date of September 24, 2018. The procurement was issued under open competition with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Zellmechanik Dresden GMBH for $120,000 on August 4, 2020, for procurement of the Accelerator for Probing the Biophysical Regulation of Metastasis. Performance will take place in Germany. The order carries a firm fixed price and was issued without a set-aside. The ultimate completion date is November 17, 2020. The procurement originated from a special notice posted June 15, 2020, with a closing date of June 25, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Zellmechanik Dresden GMBH for $27,500 on March 23, 2021, for one inverted microscope and one motorized stage upgrade on a government-owned accelerator system supporting biophysical metastasis research. Performance is located in Germany. The order is firm fixed price with an ultimate completion date of June 1, 2021. The procurement originated from a pre-solicitation opportunity posted January 19, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) valued at $23,348.60 on August 24, 2018, with ultimate completion on August 23, 2019. No set-aside was used. Performance occurs in Bethesda, Maryland. The order is a firm fixed price commercial purchase; specific requirements are not detailed in the award notice.</p>

<p>The National Cancer Institute awarded a purchase order to Menarini Silicon Biosystems, Inc. for $18,700.00 on August 24, 2017. Performance takes place in Bethesda, Maryland. The order carries a firm fixed price and was due for completion by January 27, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) for $13,104.90 on July 3, 2018, with an ultimate completion date of July 3, 2019. The order, issued on a firm fixed price basis with no set-aside, procures antibodies. Place of performance is Bethesda, Maryland.</p>

The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) valued at $177,816 on September 24, 2021, for a laser capture microdissection system. The order was issued as a simplified acquisition without a set-aside to de-obligate expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a). Work is performed at Bethesda, Maryland. The order's ultimate completion date was October 22, 2021. The originating solicitation, posted...

<p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) on September 7, 2017, with a ceiling value of $6,088.50. The order carries no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is October 9, 2017. Pricing is firm fixed price. The specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Peptides &amp; Elephants GMBH for $7,675.00 on November 8, 2017, for laboratory supplies. Place of performance is Germany. The order is firm fixed price with an ultimate completion date of November 8, 2018. No small business set-aside applied.</p>